EGFR and non-small cell lung carcinoma: <b>Purpose:</b> The role of targeted therapy in the neoadjuvant field of stage IIIA epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) is still controversial.